Patents Assigned to Essentialis, Inc.
  • Methods for treating subjects with Prader-Willi syndrome
    Patent number: 12419895
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Grant
    Filed: May 30, 2025
    Date of Patent: September 23, 2025
    Assignee: ESSENTIALIS, INC.
    Inventor: Neil M. Cowen
  • Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
    Patent number: 12343348
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Grant
    Filed: December 19, 2024
    Date of Patent: July 1, 2025
    Assignee: ESSENTIALIS, INC.
    Inventor: Neil M. Cowen
  • Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
    Patent number: 12178823
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Grant
    Filed: September 4, 2024
    Date of Patent: December 31, 2024
    Assignee: ESSENTIALIS, INC.
    Inventor: Neil M. Cowen
  • Salts of potassium ATP channel openers and uses thereof
    Patent number: 11786536
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: October 17, 2023
    Assignee: ESSENTIALIS, INC.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Salts of potassium ATP channel openers and uses thereof
    Patent number: 11045478
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 29, 2021
    Assignee: ESSENTIALIS, INC.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
    Patent number: 10456408
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 29, 2019
    Assignee: ESSENTIALIS, INC.
    Inventor: Neil M. Cowen
  • Salts of potassium ATP channel openers and uses thereof
    Patent number: 10085998
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: October 2, 2018
    Assignee: Essentialis, Inc.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
    Patent number: 10058557
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: August 28, 2018
    Assignee: Essentialis, Inc.
    Inventor: Neil M. Cowen
  • Pharmaceutical formulations of potassium ATP channel openers and uses thereof
    Patent number: 9782416
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: October 10, 2017
    Assignee: Essentialis, Inc.
    Inventor: Neil Madison Cowen
  • Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
    Patent number: 9757384
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: September 12, 2017
    Assignee: Essentialis, Inc.
    Inventor: Neil M. Cowen
  • SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
    Publication number: 20170143732
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: June 28, 2016
    Publication date: May 25, 2017
    Applicant: Essentialis, Inc.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Salts of potassium ATP channel openers and uses thereof
    Patent number: 9381202
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: July 5, 2016
    Assignee: ESSENTIALIS, INC.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME
    Publication number: 20160136178
    Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.
    Type: Application
    Filed: November 12, 2015
    Publication date: May 19, 2016
    Applicant: ESSENTIALIS, INC.
    Inventor: Neil M. Cowen
  • SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
    Publication number: 20130309301
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: November 7, 2012
    Publication date: November 21, 2013
    Applicant: Essentialis, Inc.
    Inventor: Essentials, Inc.
  • SALTS OF POTASSIUM ATP CHANNEL OPENERS AND USES THEREOF
    Publication number: 20130225806
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 29, 2013
    Applicant: Essentialis, Inc.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Salts of potassium ATP channel openers and uses thereof
    Patent number: 7799777
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: September 21, 2010
    Assignee: Essentialis, Inc.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Salts of potassium ATP channel openers and uses thereof
    Patent number: 7572789
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: August 11, 2009
    Assignee: Essentialis, Inc.
    Inventors: Neil M. Cowen, Kenneth B. Kashkin, Khaled A. Yamout